 Home > Active Ingredient News > Antitumor Therapy > Kong Delin, Hu Yongxian, Zhejiang University, et al.: It is safe and effective for patients with extramedullary recurrent lymphocytic leukemia after autologous CAR-T treatment to apply donor-derived CD19 CAR-T treatment again

Kong Delin, Hu Yongxian, Zhejiang University, et al.: It is safe and effective for patients with extramedullary recurrent lymphocytic leukemia after autologous CAR-T treatment to apply donor-derived CD19 CAR-T treatment again

 Last Update: 2022-11-15
 Source: Internet
 Author: User

Tags

vegetable seeds online

pleiades journal

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Content introduction

Chinese Summary:

Objective:

Although chimeric antigen-affected T (CAR-T) cell bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shown significant therapeutic efficacy for refractory/relapsed B-cell malignancies, a small proportion of patients will experience disease recurrence
.

Innovation Points:

Donor-derived CAR-T cells can exert antitumor effects through the anti-leukemic effect of grafts, and their safety is good, so they can be used as one of
the options for the treatment of relapsed B line acute lymphoblastic leukemia (B-ALL) after transplantation.

Method:

This study reported a 62-year-old female patient who was diagnosed with CD19-positive B-ALL
.
After the first autologous CAR-T bridging allogeneic hematopoietic stem cell therapy, patients quickly developed extramedullary recurrence
.
The patient was subsequently treated
with donor-derived CD19 CAR-T.
One month after the infusion, routine bone marrow tests showed no leukemia cells in the medulla and negative
MRD.
In addition, positron emission computed tomography (PET/CT) showed complete disappearance
of extramedullary lesions.

Conclusion:

Second-allogeneic CAR-T therapy can treat extramedullary leukemia quickly and effectively, and the risk of graft-versus-host disease (GVHD) is low, so it can be used as one of
the treatment options for disease recurrence after transplantation.

Keyword groups:

Chimeric antigen receptor T cells (CAR-T); Extramedullary recurrence; Allogeneic hematopoietic stem cell transplantation

Author:

Delin KONG, Tingting YANG, Jia GENG, Ruirui JING, Qiqi ZHANG, Guoqing WEI, He HUANG, Yongxian HU

Citation format of this article:

Delin KONG, Tingting YANG, Jia GENG, Ruirui JING, Qiqi ZHANG, Guoqing WEI, He HUANG, Yongxian HU.
Secondary donor‐derived CD19 CAR‐T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR‐T therapy[J].
Journal of Zhejiang University Science B, 2022, 23(10): 876‐880.

https://doi.
org/10.
1631/jzus.
B2200128

Essential introduction to this article:

Full text download address:

https://jzus.
zju.
edu.
cn/oldversion/opentxt.
php?doi=10.
1631/jzus.
B2200128

About this journal

Journal of Zhejiang University (English Edition) Series B: Biomedicine and Biotechnology, referred to as JZUS-B, is a comprehensive English monthly journal
of biology.
JZUS-B has been included in SCI-E since 2008, with a latest impact factor of 5.
552, and has been searched
by well-known domestic and foreign platforms such as MEDLINE/PubMed, PMC, Scopus, BA, BIOSIS Previews, etc.

JZUS-B receives articles in life sciences, medicine, pharmacy, biochemistry, biotechnology and bioengineering, agronomy, ecology, and zoology
.
Article types include Review, Article, Perspective, Viewpoint, Editorial, Correspondence, etc
.

The journal has always implemented a strict international peer review mechanism, with an average review period of 42 days and an average acceptance time of 53 days
.
After acceptance, the article will be immediately online in Press and will generally be officially published
within 2 months.

"Content-oriented, flexible form" is the characteristic of
this journal.
JZUS-B welcomes outstanding scholars at home and abroad to submit the latest scientific research achievements, controversial topics, review papers and organize the publication of hot albums
.

Journal Springer homepage:

style="min-height: 14px;outline: 0px;max-width: 536px;box-sizing: border-box;overflow-wrap: break-word !important;" _msthash="251726" _msttexthash="586040">Online Submission Address:

style="outline: 0px;max-width: 100%;box-sizing: border-box !important;overflow-wrap: break-word !important;">

Zhejiang University Journal English version is a number of English academic journals of the general name, the scope of collection covers all directions of science, engineering, agriculture and medicine, welcome to submit to our journal, you can pay attention to our journal public number zdxbywb for more information
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.